AP NEWS

Global Companion Diagnostics (CDx) Market 2018-2025: Opportunities in Data Science for Companion Diagnostics Applications - ResearchAndMarkets.com

October 2, 2018

DUBLIN--(BUSINESS WIRE)--Oct 2, 2018--The “Global Companion Diagnostics (CDx) Market: Focus on Technology, Indication, Country-wise Analysis, Regulatory Framework, and Competitive Landscape - Analysis and Forecast, 2018-2025” report has been added to ResearchAndMarkets.com’s offering.

The global healthcare expenditure was valued approximately $7 trillion in 2015 and is expected to reach over $8.5 trillion by 2020, owing to the increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and respiratory diseases, among others with global companion diagnostics market expected to reach $4.1 billion by 2025

In addition, the rise in global geriatric population and the increase in incidence of communicable diseases, neurodegenerative diseases, and infectious diseases, among others are escalating the economic, social, and clinical burden, across the globe, thereby increasing pricing pressure on the pharmaceutical as well as diagnostic companies. Acknowledging the criticality of the situation, government bodies of several nations have been restructuring their regulatory framework and norms to help companies in reducing treatment costs and expand accessibility to advance healthcare solutions.

On the other hand, the healthcare companies are trying to reduce the unnecessary healthcare expenditure by enabling novel treatment approaches and developing cost-effective products based on advanced technologies. Advent of precision medicine, a patient-centric treatment approach based on biomarker study, is perceived to be promising in driving a paradigm shift in the healthcare industry.

This biomarker-based, targeted medication would not only facilitate in eliminating the uncertainty of trial and error method of medications, but also eliminate unnecessary healthcare expenditure.

Key Topics Covered:

Executive Summary

1 Market Overview

2 Market Dynamics

3 Competitive Insights

4 Regulatory Framework

5 Global Companion Diagnostics Market: Analysis and Forecast

6 Global Companion Diagnostics Market (by Technology)

7 Global Companion Diagnostics Market (by Indication)

8 Global Companion Diagnostics Market (by Region)

9 Company Profiles

Abbott Laboratories Agilent Technologies, Inc. ARUP Laboratories bioMrieux SA Danaher Corporation F. Hoffmann-La Roche AG Illumina, Inc. Invivoscribe Technologies, Inc. MolecularMD Corporation Myriad Genetics, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc. ArcherDx, Inc. Exosome Diagnostics, Inc. NeoGenomics, Inc. MDxHealth, Inc. NanoString Technologies, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/b9jf5k/global_companion?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005684/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,In Vitro Diagnostics

KEYWORD:

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/02/2018 10:19 AM/DISC: 10/02/2018 10:19 AM

http://www.businesswire.com/news/home/20181002005684/en

AP RADIO
Update hourly